نتایج جستجو برای: meropenem

تعداد نتایج: 3072  

2016
John E. Mazuski Leanne B. Gasink Jon Armstrong Helen Broadhurst Greg G. Stone Douglas Rank Lily Llorens Paul Newell Jan Pachl

BACKGROUND When combined with ceftazidime, the novel non-β-lactam β-lactamase inhibitor avibactam provides a carbapenem alternative against multidrug-resistant infections. Efficacy and safety of ceftazidime-avibactam plus metronidazole were compared with meropenem in 1066 men and women with complicated intra-abdominal infections from 2 identical, randomized, double-blind phase 3 studies (NCT014...

Journal: :Antimicrobial agents and chemotherapy 2013
Arnold Louie Weiguo Liu Steven Fikes David Brown G L Drusano

Pseudomonas aeruginosa pneumonia remains a difficult therapeutic problem. Optimal doses and modes of administration of single agents often do not result in acceptable outcomes. Further, emergence of resistance occurs frequently in this setting with single-agent chemotherapy. The purpose of these experiments was to evaluate combination chemotherapy with meropenem plus tobramycin for P. aeruginos...

Journal: :Antimicrobial agents and chemotherapy 1997
E Di Modugno R Broggio I Erbetti J Lowther

GV129606 is a new parenteral trinem antibiotic belonging to the beta-lactam class. It combines broad-spectrum activity (against gram-negative and -positive bacteria, aerobes and anaerobes), with high potency and resistance to beta-lactamases. Comparative in vitro and in vivo antibacterial activities were determined for GV129606 against more than 400 recent clinical isolates (aerobes, including ...

2016
Marion J Skalweit Mei Li

Genetic screening of Pseudomonas aeruginosa (PSDA) and Acinetobacter baumannii (ACB) reveals genes that confer increased susceptibility to β-lactams when disrupted, suggesting novel drug targets. One such target is lytic transglycosylase. Bulgecin A (BlgA) is a natural product of Pseudomonas mesoacidophila and a lytic transglycosolase inhibitor that works synergistically with β-lactams targetin...

2016
Bing Fan Jie Guan Xiumei Wang Yulong Cong

Few effective therapeutic options are available for treating severe infections caused by extensively drug-resistant Acinetobacter baumannii (XDR-AB). Using a murine thigh-infection model, we examined the in vivo efficacy of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin, or sulbactam against 12 XDR-AB strains. Colistin, tigecycline, rifampin, and sulbact...

Journal: :Antimicrobial agents and chemotherapy 2001
S F Epp T Köhler P Plésiat M Michéa-Hamzehpour J Frey J C Pechère

We investigated the unusual susceptibility to meropenem observed for seven imipenem-resistant clinical isolates of Pseudomonas aeruginosa. These strains were genetically closely related, expressed OprD, as determined by Western blot analyses, and were resistant to imipenem (>5 microg/ml) but susceptible to meropenem (<1 microg/ml). The oprD genes from two isolates were entirely sequenced, and t...

2017
Meredith A. Hackel Masakatsu Tsuji Yoshinori Yamano Roger Echols James A. Karlowsky Daniel F. Sahm

Cefiderocol (formerly S-649266) is an investigational siderophore cephalosporin. Iron-depleted cation-adjusted Mueller-Hinton broth (ID-CAMHB) was prepared according to the Clinical and Laboratory Standards Institute (CLSI) protocol and used to perform broth microdilution testing of cefiderocol against a 2014-2015 collection of clinical isolates of Gram-negative bacilli from North America (n = ...

Journal: :Antimicrobial agents and chemotherapy 2014
T Tängdén R A Hickman P Forsberg P Lagerbäck C G Giske O Cars

Combination therapy is recommended for infections with carbapenemase-producing Klebsiella pneumoniae. However, limited data exist on which antibiotic combinations are the most effective. The aim of this study was to find effective antibiotic combinations against metallo-beta-lactamase-producing K. pneumoniae (MBL-KP). Two VIM- and two NDM-producing K. pneumoniae strains, all susceptible to coli...

Journal: :Antimicrobial agents and chemotherapy 2016
Martin Wiesholzer Petra Pichler Gottfried Reznicek Michaela Wimmer Manuel Kussmann Peter Balcke Heinz Burgmann Markus Zeitlinger Wolfgang Poeppl

The objective of this study was to determine the pharmacokinetic profile of meropenem in automated peritoneal dialysis (APD) patients. In 6 patients without peritonitis, a single dose of 0.5 g of meropenem was applied intraperitoneally (i.p.) or intravenously (i.v.) and concentrations in serum and dialysate were measured at specified intervals over 24 h with high-performance liquid chromatograp...

2016
Islam M. Ghazi Jared L. Crandon Emil P. Lesho Patrick McGann David P. Nicolau

INTRODUCTION We aimed to describe the in vivo efficacy of meropenem, in addition to cefepime and levofloxacin as comparators against VIM-producing Pseudomonas aeruginosa and compare the findings to our previous observations with Enterobacteriaceae. METHODS Eight clinical P. aeruginosa isolates with meropenem MICs from 4 to 512 mg/L were studied in a murine neutropenic thigh infection model. A...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید